Alesis

What Alesis does

Alesis LLC, operating as Alesis Medical, is a Cocoa Beach, Florida-based private medical device company founded in 2011 that has developed and commercialized the Alesis OSA1, the first FDA-cleared non-invasive device targeting the pathophysiologic mechanism of obstructive sleep apnea (OSA) through localized adipose reduction in the upper airway. The device uses patented high-powered non-laser photonic energy to activate mitochondrial cytochrome c oxidase in adipocytes, triggering lipolysis without thermal damage or destruction of fat cells; treatment consists of six 12-minute in-office sessions over three weeks. The technology is supported by three FDA 510(k) clearances (K160880, K150336, K202361), 11 utility patents across 31 countries, an 11-year safety record with zero adverse outcomes, and a randomized IRB trial (NCT06949969) showing 100% submental fat reduction and 80% of subjects achieving 51-85% AHI improvement.

The company sells exclusively through joint venture partnerships with sleep medicine practices, sleep centers, and dual board-certified sleep dentists under the Alesis Apnea Network, rather than through traditional medical device distribution. Revenue is generated from hardware sales of the OSA1 (manufactured in the U.S. by Photonica USA, LLC) combined with structured certification, training, and practice integration services delivered on multi-year contracts with quote-based pricing. The primary customer segments are sleep medicine practices and sleep dentists who serve the 40-50% of OSA patients who discontinue CPAP therapy, with secondary focus on CPAP-intolerant patients as end users. As of June 2026, Alesis had expanded to five U.S. states and was executing a stated cadence of one to three new sleep center JV partnerships per week, with the founder Terry J. Ward, Sr., M.H.A. serving as Managing Director & CEO and personally handling physician inquiries.

Name

Alesis

Legal name

Alesis LLC

Website

https://AlesisMedical.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

11–50 employees

Short description

Alesis Medical develops and distributes the Alesis OSA1, an FDA-cleared non-invasive photonic lipolysis device that treats obstructive sleep apnea by reducing upper airway fat, sold to sleep medicine practices and sleep dentists via joint venture partnerships.

Ownership category

akta.pro rank

Product category

Sleep Apnea Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Sleep Apnea Therapy Devices (CPAP/APAP/BiPAP/ASV) (HLAHAGAA)

akta.pro secondary industry

Sleep & Airway Orthodontics (OSA Appliances/Expansion) (HLABABAI)

Keywords

• Medical device manufacturer
• Sleep apnea treatment
• Photonic lipolysis devices
• Non-invasive therapy
• FDA-cleared devices

Headquarters

HQ city

Cocoa Beach

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Marketing or Sales, Personnel, Operations, Infrastructure

Revenue model

1. Alesis OSA1 Device Sales: Medical device sales to sleep medicine practices and dental specialists through joint venture partnerships. The company manufactures the device in America (Photonica USA, LLC) and distributes directly to physician practices offering the treatment.
2. Practice Integration & Training Services: Structured certification program with continuing medical education for treatment administration and patient management, comprehensive treatment guidelines, and outcome tracking systems provided to physician partners.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Alesis develops, manufactures, and distributes the FDA-cleared Alesis OSA1, a non-invasive medical device that uses patented high-powered non-laser photonic energy (photonic lipolysis) to reduce fat deposits in the upper airway for the treatment of obstructive sleep apnea. The device is administered through six 12-minute in-office sessions over three weeks and is sold to sleep medicine practices, sleep centers, and dual board-certified sleep dentists through joint venture partnerships under the Alesis Apnea Network.

Product overview

Alesis offers a single unified product: the Alesis OSA1, an FDA-cleared medical device for treating obstructive sleep apnea. The device uses photonic lipolysis technology to reduce fat deposits in the upper airway, targeting the pathophysiologic root cause of OSA rather than managing symptoms. Manufactured in the USA by Photonica USA, LLC, the product is offered to sleep medicine and dental practices through a partnership/referral network model (Alesis Apnea Network) rather than as a traditional software platform with modules.

Differentiator

Problem solved

Functional benefit

Brands

• Alesis OSA1: FDA-cleared medical device using photonic lipolysis to treat obstructive sleep apnea through localized adipose reduction

Products and services

• Alesis OSA1 FDA-cleared, non-invasive medical device using patented high-powered non-laser photonic energy to perform photonic lipolysis, reducing submental, tongue, and parapharyngeal fat deposits that contribute to obstructive sleep apnea. Administered as six 12-minute in-office treatments over three weeks. Targeted at sleep medicine practices, sleep centers, and sleep dentists treating CPAP-intolerant OSA patients; manufactured in the USA by Photonica USA, LLC.
• Alesis OSA1 Practice Integration & Certification Program Structured onboarding and certification program for physician partners adopting the Alesis OSA1, including continuing medical education for treatment administration and patient management, comprehensive treatment guidelines, outcome tracking systems, patient education materials, and opportunities to participate in multi-site clinical research. Targeted at sleep medicine physicians and sleep dentists integrating the OSA1 into their practices.

Quantifiable outcome

• 86% reduction in AHI (Apnea-Hypopnea Index) - from 22.4 to 3.1 in first patient case study
• +5 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered core and flagship.

• Chicago Sleep Medicine Partnership (Illinois)coreStrategic or Co-development Partner · 8 June 2026Joint venture expanding the Alesis Apnea Network to Chicago, Illinois. Partnership involves sleep medicine specialists offering the FDA-cleared Alesis OSA1 device for obstructive sleep apnea treatment.
• Upper Michigan Sleep Medicine PartnershipcoreStrategic or Co-development Partner · 8 June 2026Joint venture expanding the Alesis Apnea Network to Upper Michigan. Partnership involves dental specialists offering the FDA-cleared Alesis OSA1 device for obstructive sleep apnea treatment.
• South Florida Sleep Medicine PartnershipcoreStrategic or Co-development Partner · 8 June 2026Joint venture expanding the Alesis Apnea Network to South Florida. Partnership involves sleep medicine specialists offering the FDA-cleared Alesis OSA1 device for obstructive sleep apnea treatment.
• Dr. Lyly Fisher, DDSflagshipStrategic or Co-development Partner · 27 May 2026Joint venture partnership with Dr. Lyly Fisher, a dual board-certified sleep dentist in Seattle and Renton, Washington, making her the first provider in the Seattle area to offer the Alesis OSA1 FDA-cleared medical device for obstructive sleep apnea patients who cannot tolerate CPAP therapy. This partnership marks Alesis LLC's first West Coast location as part of a national expansion strategy.
• Photonica USA, LLCcoreOEM/ Whitelabel/ Licensing PartnerContract manufacturer of the Alesis OSA1 device in the United States. Maintains quality assurance standards for the medical device with 11-year safety record.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• ResMed: ResMed is the global CPAP/BiPAP market leader and the dominant incumbent OSA therapy. It competes with Alesis for the same OSA patient pool, although its PAP-based approach has the 40-50% adherence problem that Alesis positions against.
• Philips Respironics: Philips Respironics is one of the two dominant CPAP manufacturers globally and a broad respiratory/sleep therapy incumbent. It competes with Alesis for OSA patients, although recent CPAP recall-related reputation damage creates an opening for Alesis' alternative approach.
• Fisher & Paykel Healthcare: Fisher & Paykel Healthcare manufactures CPAP machines, humidification, and respiratory care products. It is a broad incumbent in the OSA therapy market and competes with Alesis for sleep medicine specialist relationships, though in PAP rather than photonic modalities.

Direct peers

• SomnoMed: SomnoMed is a global leader in custom oral appliance therapy for OSA, distributed through sleep dentists and sleep medicine specialists. It is a channel and indication peer to Alesis — both compete for the CPAP-intolerant OSA patient via the dental sleep medicine channel.
• ProSomnus Sleep Technologies: ProSomnus manufactures precision oral appliance therapy devices for OSA. It competes with Alesis for the same CPAP-intolerant patient segment via dental/sleep medicine channels, though it relies on ongoing nightly wear rather than a finite treatment course.
• Inspire Medical Systems: Inspire Medical Systems markets an FDA-cleared hypoglossal nerve stimulation implant for moderate-to-severe OSA patients who cannot tolerate CPAP — the closest direct competitor to Alesis OSA1 in targeting the CPAP-intolerant segment with an implanted/alternative procedural therapy rather than PAP.
• Signifier Medical Technologies: Signifier's eXciteOSA is a daytime neuromuscular tongue-stimulation device FDA-cleared for mild OSA and snoring. Like Alesis, it targets the anatomic substrate of OSA in patients seeking CPAP alternatives, with a clinic-and-home procedural model.

Emerging players

• Nyxoah: Nyxoah develops the Genio hypoglossal nerve stimulation system for OSA, competing in the same CPAP-intolerant procedural-therapy space as Inspire and Alesis. It is a comparable emerging procedural alternative targeting the root cause of OSA via neurostimulation.

Others

• Cynosure (Hologic): Cynosure, now part of Hologic, markets energy-based aesthetic devices including body contouring and lipolysis systems. While not an OSA device, the underlying photonic/energy-based lipolysis mechanism overlaps with Alesis' technology and represents a potential adjacent competitor or acquirer.
• ApniCure: ApniCure previously developed the Winx oral negative-pressure sleep therapy system for OSA as an alternative to CPAP. Although the company has wound down operations, it represents a historically relevant OSA alternative-therapy peer and informs the challenging commercialization dynamics Alesis faces.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/alesis-medical

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alesis